RxDoctor Payments Data

Ana Blackmon, MD

Internal Medicine · Houston, TXNPI 1962402446

Payments from drug & device makers

$1,574in general payments, 2019–2025

Across 80 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$324
  • Lilly USA, LLC$200
  • Novo Nordisk$181
  • Abbott$133
  • Amgen$105
  • AbbVie$102
  • plus $528 from 14 others

What the payments were for

  • Food & beverage$1,56299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,574 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$105,781
Medicare patients
280
Services billed
1,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide60$71,848
JardianceEmpagliflozin64$64,946
OzempicSemaglutide52$52,301
Repatha SureclickEvolocumab37$43,899
TrulicityDulaglutide18$35,854
JanuviaSitagliptin Phosphate24$27,402
EliquisApixaban27$26,712
FarxigaDapagliflozin Propanediol18$23,108
XareltoRivaroxaban18$17,781
InvokanaCanagliflozin16$17,322
VascepaIcosapent Ethyl33$16,198
Repatha SyringeEvolocumab13$13,190
SynthroidLevothyroxine Sodium108$10,897
GemtesaVibegron12$6,036
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$5,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$200$107,70278 claims
Novo NordiskOzempic$181$52,30152 claims
Johnson & JohnsonXarelto, Invokana$46$35,10334 claims
PfizerEliquis$324$26,71227 claims
AbbVieSynthroid$102$10,897108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →